AZBio and its partners have programs strategically designed to help improve access to capital for our Arizona Life Science Industry and to preserve capital through AZBio Purchasing Power Programs.
How well they work depends on you.Continue reading
Author Archive: AZBio
Castle Biosciences reports study results from DecisionDx-EC multi-analyte test for esophageal cancer
Castle Biosciences Inc. today announced study results from its proprietary multi-analyte test DecisionDx-EC, which is designed to determine which patients with esophageal cancer are likely to respond or not respond to standard pre-surgical chemoradiation therapy. The results were reviewed in a poster presentation at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO). The data demonstrate thebiomarker test’s ability to accurately identify two types of patients: those who are likely to respond to pre-surgical chemoradiation therapy (CTRT) and should continue to receive the standard therapy; and those unlikely to respond to CTRT and could instead move rapidly to surgery or other more effective therapies.Continue reading
Xeridiem expands leadership team
Xeridiem has expanded the leadership team with the appointment of Shubroto Chattopadhyay as Senior Business Development and Marketing Director, reporting to Xeridiem President, Joseph Lee. Mr. Chattopadhyay comes to Xeridiem from Parker Hannifin Corporation, Medical Systems Division, where he served as Market Manager and Marketing Communications.Continue reading
Penny Wise and Pound Foolish – Castellani answers critics on drug prices with facts.
Castellani Statement on Prescription Drug Costs
Washington, D.C. (May 29, 2014) – The Pharmaceutical Research and Manufacturers of America (PhRMA) President and CEO John Castellani today released the following statement on the cost and value of medicines:Continue reading
UA Researchers Identify Viral Genes That Control Human Cytomegalovirus Reactivation
Identifying the mechanisms that determine CMV latency could lead to targeted therapies that prevent CMV-related disease.Continue reading
Provista Diagnostics Expands Exclusive License Agreement for Biomarker Technologies Developed at the Biodesign Institute at Arizona State University
Provista Diagnostics, Inc., a molecular diagnostics company developing and commercializing proteomic-based diagnostic, prognostic and monitoring tests for cancers affecting women, announced it has expanded its exclusive license agreement for certain biomarker and autoantibody technologies identified by researchers Joshua LaBaer, M.D., Ph.D. and Karen Anderson, M.D., Ph.D. of the Biodesign Institute of Arizona State University. The license provides Provista with access to patents, proprietary technology, materials, processing techniques and protocols necessary for detection of certain autoantibodies and use of certain biomarkers. Continue reading
Moving Up
In January 2013 at TEDx Beacon Street, Harvard Business School’s Rosabeth Moss Kanter shared Six Keys to Leading Positive Change. Let’s look at how can we apply them to grow our Bioscience and Healthcare Industry here in Arizona so we can individually and collectively keep things moving up.Continue reading
Job Alert: Join ASU’s Entrepreneurship & Innovation Team
Exciting employment opportunities are currently available with the Entrepreneurship & Innovation (EI) Team at ASU. Continue reading
DNA nanotechnology places enzyme catalysis within an arm’s length
Using molecules of DNA like an architectural scaffold, Arizona State University scientists, in collaboration with colleagues at the University of Michigan, have developed a 3-D artificial enzyme cascade that mimics an important biochemical pathway that could prove important for future biomedical and energy applications.Continue reading
Organizational Changes Strengthen and Expand Celgene Leadership Team
Celgene Corporation (CELG) today announced organizational changes that will go into effect on August 1, 2014.Continue reading